Aurora Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Aurora Bundle
Download Your Competitive Advantage
Aurora’s BCG Matrix slices through the noise—showing which products are Stars, Cash Cows, Dogs, or Question Marks and why it matters to your P&L. This preview gives you a quick read; the full report maps every quadrant with data-backed moves and clear priorities. Purchase the complete BCG Matrix for the Word + Excel deliverables and start reallocating capital with confidence.
Stars
Premium medical portfolio (EU-GMP)
Premium medical portfolio (EU-GMP) holds top-quartile market share in a European market valued at roughly €300B (pharma/medtech combined) with ~4% CAGR, delivering strong gross margins above 50% and stable demand from clinics and pharmacies; ongoing compliance and education spend is required. Keep feeding it—this engine can become a cash cow as growth normalizes, and pull-through on new indications widens the moat.
Top-selling dried flower SKUs (adult-use)
Top-selling dried flower SKUs are Aurora’s shelf-moving flagship strains across key provinces, commanding a high share in a still-expanding adult-use dried-flower category. They require steady promotions, retail activation and tight supply planning to protect velocity through freshness and consistency. These leaders fund marketing and operations, then transition into dependable cash cows as category growth normalizes.
International medical exports (Germany-led)
High-growth access via Germany’s ~18,000 pharmacies with strict quality bars gives Aurora leverage in premium channels. Share becomes meaningful in supply-constrained niches, but market education and regulatory navigation increase cash burn. If reimbursement widens and physician adoption compounds, revenue growth can accelerate. Well managed, this remains a star until market maturation.
High-potency vapes and concentrates
High-potency vapes and concentrates are a Stars subcategory, growing ~20% YoY in 2024 and representing roughly 35% of vape revenue; premium ASPs run 40–60% above standard SKUs and repeat-buyer rates near 65%. Share gains derive from potency, flavor and device reliability plus compliant marketing, but sustaining growth needs constant innovation and capex for cartridge/packaging lines (~$1–3M per line). Fund now to lock brand preference before the curve flattens.
- Growth: ~20% YoY (2024)
- Revenue share: ~35% of vape category
- Repeat buyers: ~65%
- Premium ASPs: +40–60%
- Capex: $1–3M per production line
Pharmacy and clinic distribution footprint
Pharmacy and clinic distribution footprint is a Stars asset for Aurora: wide, compliant access is a competitive advantage as the market onboards patients in 2024. Expect high growth as prescriber comfort rises and strong share where Aurora is listed. Keep investing in medical reps, education, and data to compound brand equity and unit economics.
- Market position: Stars in 2024
- Strategy: scale reps, training, real-world data
- Effect: stronger unit economics and brand equity
€300B EU medtech play: >50% margins, high-potency vapes +20% - invest now
Premium medical portfolio and top dried-flower SKUs are Stars: addressable EU pharma/medtech market ~€300B (4% CAGR), gross margins >50%, Germany pharmacy channel ~18,000 outlets. High-potency vapes grew ~20% YoY in 2024, ~35% of vape revenue, repeat buyers ~65%, premium ASPs +40–60%. Invest in supply, marketing and capex ($1–3M/line) to lock share before maturation.
| Metric | Value (2024) |
|---|---|
| Market size | €300B |
| CAGR | ~4% |
| Gross margin | >50% |
| Pharmacies (DE) | ~18,000 |
| Vape growth | ~20% YoY |
| Vape rev share | ~35% |
| Repeat buyers | ~65% |
| Capex/line | $1–3M |
What is included in the product
Detailed Word Document
Concise assessment of Aurora’s portfolio across Stars, Cash Cows, Question Marks and Dogs, with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page Aurora BCG Matrix placing each business unit in a quadrant for clear priorities and faster strategic decisions
Cash Cows
Established medical patient base (subscriptions)
Established medical patient subscriptions deliver stable scripts with predictable monthly reorder patterns and low annual churn of about 5%, yielding healthy gross margins near 65% in 2024. CAC is typically amortized within 6–9 months, so growth has slowed while unit economics remain strong. Minimal promotion beyond reliable service and supply is required. Milk cash flows and reinvest into next‑gen medical formats.
Value flower lines in mature provinces
Value flower lines in mature provinces
hold a dominant share (~45%) in a low-growth (~1.2% CAGR) price-sensitive segment; volume throughput keeps facilities >85% utilized, maintaining steady cash flow. Limited marketing and tight cost control keep SG&A under ~12% of sales, enabling EBIT margins near 18%. Harvest the margin without over-innovating to preserve cash generation.
Oils and tinctures with repeat prescriptions
Oils and tinctures are reliable chronic-use cash cows: staple formats for patients, low innovation pressure and strong brand stickiness, driving repeat-prescription revenues that can represent over 60% of category sales; gross margins typically sit in the 30–50% range. With the global CBD/hemp oil market ~5 billion USD in 2024, optimize packaging and fulfillment to squeeze more cash while maintaining quality and avoiding overspend.
Domestic wholesale and bulk sales
Domestic wholesale and bulk sales deliver lower margin per gram but reliable inventory turns and strong cash conversion; in 2024 the Canadian legal market approached CAD 3.9B, keeping growth modest. Share is defensible through scale, GMP compliance and distribution reach; run lean to balance inventory and capacity. Use this cash generator to fund R&D and higher-margin brand bets.
- Lower margins, high turnover
- Modest market growth, scale defensible
- Efficient ops fund R&D
White-label manufacturing for partners
Aurora’s licensed capacity and robust QA practices made its white-label manufacturing the go-to producer in FY2024, delivering steady, low-volatility revenue; growth is flat to modest but contracts are sticky and capital-light. Marketing spend is minimal; operational focus is on throughput and yield optimization to maximize cash generation. Cash flows are earmarked to fund higher-growth star categories.
- Category: Cash Cow
- 2024 role: Reliable cash generator
- Cost profile: Capital-light
- Focus: Throughput & yield
- Use of cash: Fund stars
Subscription engine: ~65% gross margin, ~5% churn; cash-positive in 6-9 months
Established subscription scripts yield stable monthly reorder with ~5% annual churn and gross margins ~65% in 2024; CAC amortizes in 6–9 months so cash generation is strong though growth is muted. Value flower lines hold ~45% share in a ~1.2% CAGR segment, EBIT ~18%. Wholesale, oils/tinctures and white‑label manufacturing provide capital‑light, steady cash used to fund R&D and star bets.
| Metric | 2024 |
|---|---|
| Subscription churn | ~5% |
| Gross margin (subs) | ~65% |
| Value flower share | ~45% |
| Segment CAGR | ~1.2% |
| EBIT (flower) | ~18% |
| Global CBD market | ~$5B |
| Canada legal market | ~CAD 3.9B |
What You’re Viewing Is Included
Aurora BCG Matrix
The file you’re previewing is the exact Aurora BCG Matrix report you’ll receive after purchase — no watermarks, no placeholders, just the finished, fully formatted document. It’s crafted for strategic clarity and ready to edit, print, or present. Buy once, download instantly, and use it immediately with zero surprises.
Dogs
Legacy high-cost cultivation sites
Legacy high-cost cultivation sites are Dogs: operating in low market growth segments with market share falling behind leaner rivals that report materially lower per-gram production costs and higher throughput efficiency.
Bloated unit costs and capital-intensive turnarounds in 2024 continued to drain cash and rarely flip economics; restructuring and CAPEX often extend payback horizons beyond acceptable ROI thresholds.
Better to consolidate or exit these sites, redeploy capital into scalable assets or debt reduction, and free the balance sheet from this drag.
Slow-moving edibles SKUs
Slow-moving edibles SKUs are niche flavors or formats with low single-digit market share on crowded shelves, often contributing less than 1% of category sales while occupying 10–15% of shelf space. Promo dollars evaporate without velocity: SKUs with sell-through under 1.0x/month generate negative promotional ROI. Cut these SKUs, clear inventory, and redeploy spend to top performers driving 70–80% of sales. Don’t chase sunk costs; reallocate to winners.
Overcrowded CBD-only lines
Overcrowded CBD-only lines face commodity pricing and little differentiation: global CBD retail sales were about $4.2B in 2024 with growth slowing to roughly 2–3%, compressing margins often below 10%. Cash is trapped in packaging, testing and compliance (lab costs up to 5–8% of revenue), yielding thin returns; best strategic move is sunset or license out rather than a costly turnaround burn.
Outdated packaging formats
Outdated bulky, non-premium or non-eco packs drag sell-through: in 2024 Aurora’s legacy formats accounted for 12% of SKUs but delivered only 4% of revenues, and retailers reduced shelf facings for those SKUs by ~28%, prioritizing compact, sustainable designs. Continue repack or retire—avoid capex to push formats the market ignores; keep only what moves.
- SKU share: 12% legacy formats
- Revenue share: 4% from outdated packs
- Retail facings cut: ~28% in 2024
Small, high-friction international pilots
Small, high-friction international pilots face heavy regulatory hurdles, tiny volumes and no brand traction; cash mainly trickles out on legal and logistics (customs, licensing, counsel) while pilots often deliver under 1% of target revenue, making ROI negative through 2024. Divest or pause until policy clarity and scale justify re-entry; prioritize markets with clear regulatory paths and >5% addressable share.
- Regulatory drag: high fixed legal/licensing spend vs negligible revenue
- Volume: pilots typically <1% of market demand, low conversion
- Action: pause/divest unless market has clear policy + >5% addressable share
Dogs draining cash — exit legacy SKUs, redeploy CAPEX to scalable assets or debt paydown
Dogs: legacy high-cost sites and slow SKUs drain cash—12% of SKUs but 4% of revenue, retail facings down ~28% in 2024; CBD lines face $4.2B global sales with growth 2–3% and margins <10% as lab/compliance costs hit 5–8%; international pilots <1% revenue. Recommend consolidate/exit, redeploy CAPEX to scalable assets or debt paydown.
| Metric | 2024 |
|---|---|
| Legacy SKU share | 12% |
| Revenue from legacy | 4% |
| Retail facings cut | ~28% |
| Global CBD sales | $4.2B (2–3% growth) |
| Lab/compliance | 5–8% rev |
| Intl pilots revenue | <1% |
Question Marks
Minor-cannabinoid therapeutics (CBG/THCV)
Minor-cannabinoid therapeutics (CBG/THCV) sit in the Question Marks quadrant: high-growth potential with early clinical interest and a global legal cannabis market near USD 40 billion in 2024, while Aurora’s share in therapeutics remains nascent (<1%), R&D-intensive and cash-hungry today. If randomized trials show efficacy and prescriber uptake follows, this can flip to Star; if not, management should cut fast.
THC/CBD beverage line
Legal cannabis beverages are a fast-growing segment—still under 5% of Canadian legal cannabis retail sales in 2024 but expanding double-digits year-over-year. Marketing intensity and cold-chain logistics materially raise COGS and trade spend, worsening unit economics versus dried flower. Pursue test-and-learn in core provinces and scale only where SKU velocity and repeat rates justify spend. Outcome should be clear within 12 months: winner or dog, no middle ground.
Expanded EU medical entries beyond Germany
UK (population 67 million) and Poland (38 million) plus other EU markets are opening beyond Germany, signaling real growth but market share must be earned through targeted commercial effort. Success requires dedicated market access teams, local distributors, and physician education programs. Invest selectively where reimbursement pathways are documented; pause or exit if policy or reimbursement timelines stall.
Clinical partnerships and indications research
Clinical partnerships and indications research are question marks: upside is a durable moat and premium pricing if approved, but timelines are long and programs are cash intensive, with phase 3 trials often costing $100–400M and multi-year timelines (typically 6–9 years to approval). Target high-probability indications, co-fund trials to de-risk, and only graduate to star when adoption is data-backed.
- Upside: durable moat, premium pricing
- Downside: long timelines, cash intensive
- Cost signal: phase 3 $100–400M
- Action: target high-probability indications, co-fund
- Exit rule: graduate to star only with real-world adoption data
Direct-to-patient digital and telehealth stack
Direct-to-patient digital and telehealth stack sits in Question Marks: strong 2024 tailwinds as the telehealth market approached US$90B and adherence programs showed double-digit uplift, but Aurora’s share is nascent. Needs product-market fit, EHR/API integrations, and scalable service ops to prove LTV/CAC. If engagement drives higher lifetime value and lowers CAC it becomes a flywheel; if not, sunset quickly.
- market: 2024 ~US$90B
- priority: PMF, integrations, ops
- success metric: LTV/CAC up
- failure trigger: low engagement → sunset
Prioritize minor-cannabinoid therapeutics; test beverages 12m; improve telehealth LTV:CAC
Question Marks: minor-cannabinoid therapeutics (global legal cannabis ~USD 40B in 2024; Aurora therapeutics <1%)—high upside if trials succeed, else cut.
Legal cannabis beverages <5% of Canadian retail in 2024; test-and-learn, decide within 12 months.
Telehealth ~US$90B 2024; pursue PMF/LTV:CAC improvement or sunset.
| Item | 2024 datapoint | Exit/graduate trigger |
|---|---|---|
| Therapeutics | 40B market; Aurora <1% | RWE adoption |
| Beverages | <5% Canada | SKU velocity |
| Telehealth | ~US$90B | LTV/CAC up |